{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T10:48:00Z","timestamp":1775213280466,"version":"3.50.1"},"reference-count":41,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001700","name":"Government of Japan Ministry of Education Culture Sports Science and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacionline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Allergy and Clinical Immunology"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.jaci.2025.11.010","type":"journal-article","created":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T17:21:58Z","timestamp":1765560118000},"page":"917-931","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Fabs targeting a C\u03b52 epitope disassemble IgE-receptor complexes and suppress anaphylaxis"],"prefix":"10.1016","volume":"157","author":[{"given":"Hexing","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8548-4424","authenticated-orcid":false,"given":"Tomoaki","family":"Ando","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiaki","family":"Maruyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeru C.J.","family":"Okumura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kumi","family":"Izawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayako","family":"Kaitani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akie","family":"Maehara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Risa","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul D.","family":"Entzminger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan K.","family":"Fleming","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuhiro","family":"Nakano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiko","family":"Maeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideo","family":"Yagita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideoki","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ko","family":"Okumura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiro","family":"Kitaura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaci.2025.11.010_bib1","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.1111\/all.14908","article-title":"The role of allergen-specific IgE, IgG and IgA in allergic disease","volume":"76","author":"Shamji","year":"2021","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2025.11.010_bib2","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.3390\/cells10071697","article-title":"Tuning IgE: IgE-associating molecules and their effects on IgE-dependent mast cell reactions","volume":"10","author":"Ando","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.jaci.2025.11.010_bib3","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.coi.2021.03.015","article-title":"The high affinity IgE receptor: a signaling update","volume":"72","author":"Blank","year":"2021","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.jaci.2025.11.010_bib4","doi-asserted-by":"crossref","first-page":"3130","DOI":"10.1016\/j.jaip.2020.04.068","article-title":"Add-on omalizumab for inadequately controlled severe pollinosis despite standard-of-care: a randomized study","volume":"8","author":"Okubo","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2025.11.010_bib5","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1038\/nri914","article-title":"Regulation of mast-cell and basophil function and survival by IgE","volume":"2","author":"Kawakami","year":"2002","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jaci.2025.11.010_bib6","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.1056\/NEJMct055184","article-title":"Omalizumab for asthma","volume":"354","author":"Strunk","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2025.11.010_bib7","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1111\/j.1365-2222.2004.1916.x","article-title":"Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma","volume":"34","author":"Holgate","year":"2004","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaci.2025.11.010_bib8","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1056\/NEJMoa1215372","article-title":"Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria","volume":"368","author":"Maurer","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2025.11.010_bib9","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1056\/NEJMoa2312382","article-title":"Omalizumab for the treatment of multiple food allergies","volume":"390","author":"Wood","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2025.11.010_bib10","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.jaci.2020.05.032","article-title":"Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials","volume":"146","author":"Gevaert","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2025.11.010_bib11","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1016\/j.jaci.2014.02.005","article-title":"Accelerated dissociation of IgE-FcepsilonRI complexes by disruptive inhibitors actively desensitizes allergic effector cells","volume":"133","author":"Eggel","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2025.11.010_bib12","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/s41467-019-13815-w","article-title":"The mechanistic and functional profile of the therapeutic anti-IgE antibody ligelizumab differs from omalizumab","volume":"11","author":"Gasser","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.jaci.2025.11.010_bib13","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1111\/all.13083","article-title":"Mechanisms of action that contribute to efficacy of omalizumab in chronic spontaneous urticaria","volume":"72","author":"Kaplan","year":"2017","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2025.11.010_bib14","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1038\/nsmb.2044","article-title":"Conformational changes in IgE contribute to its uniquely slow dissociation rate from receptor FcvarepsilonRI","volume":"18","author":"Holdom","year":"2011","journal-title":"Nat Struct Mol Biol"},{"key":"10.1016\/j.jaci.2025.11.010_bib15","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1111\/all.14222","article-title":"Structure of intact IgE and the mechanism of ligelizumab revealed by electron microscopy","volume":"75","author":"Jensen","year":"2020","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2025.11.010_bib16","doi-asserted-by":"crossref","first-page":"9975","DOI":"10.1074\/jbc.M117.776476","article-title":"Allosteric mechanism of action of the therapeutic anti-IgE antibody omalizumab","volume":"292","author":"Davies","year":"2017","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jaci.2025.11.010_bib17","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms11610","article-title":"Structural basis of omalizumab therapy and omalizumab-mediated IgE exchange","volume":"7","author":"Pennington","year":"2016","journal-title":"Nat Commun"},{"key":"10.1016\/j.jaci.2025.11.010_bib18","doi-asserted-by":"crossref","first-page":"756","DOI":"10.4161\/mabs.28394","article-title":"A novel IgE-neutralizing antibody for the treatment of severe uncontrolled asthma","volume":"6","author":"Cohen","year":"2014","journal-title":"MAbs"},{"key":"10.1016\/j.jaci.2025.11.010_bib19","doi-asserted-by":"crossref","DOI":"10.1172\/JCI157765","article-title":"IgE-neutralizing UB-221 mAb, distinct from omalizumab and ligelizumab, exhibits CD23-mediated IgE downregulation and relieves urticaria symptoms","volume":"132","author":"Kuo","year":"2022","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jaci.2025.11.010_bib20","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41467-017-02312-7","article-title":"Trapping IgE in a closed conformation by mimicking CD23 binding prevents and disrupts FcepsilonRI interaction","volume":"9","author":"Jabs","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.jaci.2025.11.010_bib21","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/nsmb.2795","article-title":"Human immunoglobulin E flexes between acutely bent and extended conformations","volume":"21","author":"Drinkwater","year":"2014","journal-title":"Nat Struct Mol Biol"},{"key":"10.1016\/j.jaci.2025.11.010_bib22","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-32200-z","article-title":"The Fab fragment of anti-IgE Cepsilon2 domain prevents allergic reactions through interacting with IgE-FcepsilonRIalpha complex on rat mast cells","volume":"8","author":"Hirano","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.jaci.2025.11.010_bib23","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1038\/s42003-024-06633-4","article-title":"Allosteric inhibition of IgE-FcepsilonRI interactions by simultaneous targeting of IgE F(ab\u2032)2 epitopes","volume":"7","author":"Hirano","year":"2024","journal-title":"Commun Biol"},{"key":"10.1016\/j.jaci.2025.11.010_bib24","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1126\/science.2523561","article-title":"Expression of high-affinity binding of human immunoglobulin E by transfected cells","volume":"244","author":"Miller","year":"1989","journal-title":"Science"},{"key":"10.1016\/j.jaci.2025.11.010_bib25","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.4049\/jimmunol.157.4.1645","article-title":"Anaphylaxis mediated through a humanized high affinity IgE receptor","volume":"157","author":"Dombrowicz","year":"1996","journal-title":"J Immunol"},{"key":"10.1016\/j.jaci.2025.11.010_bib26","doi-asserted-by":"crossref","DOI":"10.1074\/jbc.RA120.015996","article-title":"Structural basis for antigen recognition by methylated lysine-specific antibodies","volume":"296","author":"Ishii","year":"2021","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jaci.2025.11.010_bib27","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1084\/jem.127.4.717","article-title":"Heterologous carriers in the anamnestic antihapten response","volume":"127","author":"Rittenberg","year":"1968","journal-title":"J Exp Med"},{"key":"10.1016\/j.jaci.2025.11.010_bib28","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/35018500","article-title":"Structure of the Fc fragment of human IgE bound to its high-affinity receptor Fc epsilonRI alpha","volume":"406","author":"Garman","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.jaci.2025.11.010_bib29","doi-asserted-by":"crossref","first-page":"2623","DOI":"10.4049\/jimmunol.151.5.2623","article-title":"Humanization of an antibody directed against IgE","volume":"151","author":"Presta","year":"1993","journal-title":"J Immunol"},{"key":"10.1016\/j.jaci.2025.11.010_bib30","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1164\/ajrccm.164.supplement_1.2103025","article-title":"Development of a monoclonal anti-immunoglobulin E antibody (omalizumab) for the treatment of allergic respiratory disorders","volume":"164","author":"Schulman","year":"2001","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaci.2025.11.010_bib31","doi-asserted-by":"crossref","first-page":"7069","DOI":"10.1038\/s41467-021-27397-z","article-title":"Directed evolution of and structural insights into antibody-mediated disruption of a stable receptor-ligand complex","volume":"12","author":"Pennington","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.jaci.2025.11.010_bib32","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1111\/all.14724","article-title":"The role of CD23 in the regulation of allergic responses","volume":"76","author":"Engeroff","year":"2021","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2025.11.010_bib33","doi-asserted-by":"crossref","DOI":"10.1002\/cti2.1255","article-title":"Ligelizumab treatment for severe asthma: learnings from the clinical development programme","volume":"10","author":"Trischler","year":"2021","journal-title":"Clin Transl Immunol"},{"key":"10.1016\/j.jaci.2025.11.010_bib34","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1002\/ibd.20225","article-title":"Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor alpha agents","volume":"13","author":"Nesbitt","year":"2007","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.jaci.2025.11.010_bib35","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/nrd2654","article-title":"Certolizumab pegol","volume":"7","author":"Melmed","year":"2008","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.jaci.2025.11.010_bib36","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1007\/s10930-021-09996-3","article-title":"Production of soluble and functional anti-TNF-alpha Fab\u2032 Fragment in cytoplasm of E coli: investigating the effect of process conditions on cellular biomass and protein yield using response surface methodology","volume":"40","author":"Talaei","year":"2021","journal-title":"Protein J"},{"key":"10.1016\/j.jaci.2025.11.010_bib37","doi-asserted-by":"crossref","first-page":"235","DOI":"10.3109\/07388551.2013.834293","article-title":"Fc-fusion proteins and FcRn: structural insights for longer-lasting and more effective therapeutics","volume":"35","author":"Rath","year":"2015","journal-title":"Crit Rev Biotechnol"},{"key":"10.1016\/j.jaci.2025.11.010_bib38","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.tibtech.2014.11.001","article-title":"Fc fusion as a platform technology: potential for modulating immunogenicity","volume":"33","author":"Levin","year":"2015","journal-title":"Trends Biotechnol"},{"key":"10.1016\/j.jaci.2025.11.010_bib39","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/nrd1033","article-title":"Effect of pegylation on pharmaceuticals","volume":"2","author":"Harris","year":"2003","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.jaci.2025.11.010_bib40","doi-asserted-by":"crossref","first-page":"315","DOI":"10.2165\/00063030-200822050-00004","article-title":"The impact of PEGylation on biological therapies","volume":"22","author":"Veronese","year":"2008","journal-title":"BioDrugs"},{"key":"10.1016\/j.jaci.2025.11.010_bib41","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.jmb.2005.01.053","article-title":"Domain interactions in the Fab fragment: a comparative evaluation of the single-chain Fv and Fab format engineered with variable domains of different stability","volume":"347","author":"Rothlisberger","year":"2005","journal-title":"J Mol Biol"}],"container-title":["Journal of Allergy and Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674925021700?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674925021700?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T09:55:05Z","timestamp":1775210105000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091674925021700"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":41,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S0091674925021700"],"URL":"https:\/\/doi.org\/10.1016\/j.jaci.2025.11.010","relation":{},"ISSN":["0091-6749"],"issn-type":[{"value":"0091-6749","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Fabs targeting a C\u03b52 epitope disassemble IgE-receptor complexes and suppress anaphylaxis","name":"articletitle","label":"Article Title"},{"value":"Journal of Allergy and Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaci.2025.11.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American Academy of Allergy, Asthma & Immunology","name":"copyright","label":"Copyright"}]}}